Switch theme
Sign up to access all valuation multiples
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use humidifiers, masks and related consumables and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns 42% of its revenue in the US, 32% in Europe, 18% in Asia-Pacific and the remaining 8% in emerging markets. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand and Mexico and has a multichannel distribution model.
1934
7.5K+
LTM Revenue $1.2B
LTM EBITDA $392M
$12.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fisher & Paykel has a last 12-month revenue (LTM) of $1.2B and a last 12-month EBITDA of $392M.
In the most recent fiscal year, Fisher & Paykel achieved revenue of $1.0B and an EBITDA of $219M.
Fisher & Paykel expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fisher & Paykel valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2B | XXX | $1.0B | XXX | XXX | XXX |
| Gross Profit | $793M | XXX | $631M | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | $392M | XXX | $219M | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 21% | XXX | XXX | XXX |
| EBIT | $309M | XXX | $152M | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $230M | XXX | $79.0M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $19.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Fisher & Paykel's stock price is NZD 35 (or $21).
Fisher & Paykel has current market cap of NZD 20.3B (or $12.1B), and EV of NZD 20.2B (or $12.0B).
See Fisher & Paykel trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.0B | $12.1B | XXX | XXX | XXX | XXX | $0.39 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Fisher & Paykel has market cap of $12.1B and EV of $12.0B.
Fisher & Paykel's trades at 11.8x EV/Revenue multiple, and 52.5x EV/EBITDA.
Equity research analysts estimate Fisher & Paykel's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fisher & Paykel has a P/E ratio of 52.5x.
See valuation multiples for Fisher & Paykel and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.1B | XXX | $12.1B | XXX | XXX | XXX |
| EV (current) | $12.0B | XXX | $12.0B | XXX | XXX | XXX |
| EV/Revenue | 9.8x | XXX | 11.8x | XXX | XXX | XXX |
| EV/EBITDA | 30.7x | XXX | 52.5x | XXX | XXX | XXX |
| EV/EBIT | 38.9x | XXX | 80.4x | XXX | XXX | XXX |
| EV/Gross Profit | 15.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 52.5x | XXX | 125.2x | XXX | XXX | XXX |
| EV/FCF | 45.3x | XXX | 270.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFisher & Paykel's last 12 month revenue growth is 11%
Fisher & Paykel's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Fisher & Paykel's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fisher & Paykel's rule of X is 60% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Fisher & Paykel and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 45% | XXX | XXX | XXX |
| Rule of 40 | 34% | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 60% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fisher & Paykel acquired XXX companies to date.
Last acquisition by Fisher & Paykel was XXXXXXXX, XXXXX XXXXX XXXXXX . Fisher & Paykel acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Fisher & Paykel founded? | Fisher & Paykel was founded in 1934. |
| Where is Fisher & Paykel headquartered? | Fisher & Paykel is headquartered in New Zealand. |
| How many employees does Fisher & Paykel have? | As of today, Fisher & Paykel has 7.5K+ employees. |
| Who is the CEO of Fisher & Paykel? | Fisher & Paykel's CEO is Mr. Lewis Gradon. |
| Is Fisher & Paykel publicy listed? | Yes, Fisher & Paykel is a public company listed on NZE. |
| What is the stock symbol of Fisher & Paykel? | Fisher & Paykel trades under FPH ticker. |
| When did Fisher & Paykel go public? | Fisher & Paykel went public in 1979. |
| Who are competitors of Fisher & Paykel? | Similar companies to Fisher & Paykel include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Fisher & Paykel? | Fisher & Paykel's current market cap is $12.1B |
| What is the current revenue of Fisher & Paykel? | Fisher & Paykel's last 12 months revenue is $1.2B. |
| What is the current revenue growth of Fisher & Paykel? | Fisher & Paykel revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Fisher & Paykel? | Current revenue multiple of Fisher & Paykel is 9.8x. |
| Is Fisher & Paykel profitable? | Yes, Fisher & Paykel is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Fisher & Paykel? | Fisher & Paykel's last 12 months EBITDA is $392M. |
| What is Fisher & Paykel's EBITDA margin? | Fisher & Paykel's last 12 months EBITDA margin is 32%. |
| What is the current EV/EBITDA multiple of Fisher & Paykel? | Current EBITDA multiple of Fisher & Paykel is 30.7x. |
| What is the current FCF of Fisher & Paykel? | Fisher & Paykel's last 12 months FCF is $266M. |
| What is Fisher & Paykel's FCF margin? | Fisher & Paykel's last 12 months FCF margin is 22%. |
| What is the current EV/FCF multiple of Fisher & Paykel? | Current FCF multiple of Fisher & Paykel is 45.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
